2022. Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s72. DOI:https://doi.org/10.25251/skin.6.supp.72.